Global Methicillin-resistant Staphylococcus Aureus Drugs Market Size Study & Forecast, by Drug Class (Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Other Drug Classes), By Route of Administration (Oral Administration, Paren

Global Methicillin-resistant Staphylococcus Aureus Drugs Market Size Study & Forecast, by Drug Class (Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Other Drug Classes), By Route of Administration (Oral Administration, Parenteral Administration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Analysis, 2023-2030

Global Methicillin-resistant Staphylococcus Aureus Drugs Market is valued approximately at USD XX billion in 2022 and is anticipated to grow with a growth rate of more than 3.6% over the forecast period 2023-2030. sMethicillin-resistant Staphylococcus aureus (MRSA) drugs are medications developed to treat infections caused by Staphylococcus aureus bacteria that have become resistant to methicillin and other beta-lactam antibiotics. MRSA is a significant public health concern due to its ability to cause severe infections such as skin and soft tissue infections, pneumonia, and bloodstream infections. MRSA drugs, including antibiotics such as vancomycin, linezolid, and daptomycin, target bacterial growth mechanisms to prevent infection spread and aid the immune system in combating the bacteria. The rise in the global incidences of infections and demand for novel therapies and the growing concerns regarding Multidrug-Resistant (MDR) strains are the key driving factors for the market demand across the globe. Also, the increased focus on infection control and ongoing advancements in the pipeline space, where major pharmaceutical companies are actively progressing the future development potential of treatments targeting methicillin-resistant Staphylococcus aureus (MRSA) infections are further attributing to the market expansion globally.

In addition, the growth of the Methicillin-resistant Staphylococcus Aureus (MRSA) drugs market is propelled by the global rise in MRSA infections. The World Health Organization stated that the global, percentage of bloodstream infections caused by methicillin-resistant Staphylococcus aureus (MRSA) has increased significantly, rising by 14% from 21% in 2016 to 25% in 2019 and further to 35% in 2020. Also, according to a July 2021 study titled ""Methicillin-Resistant Staphylococcus Aureus,"" MRSA infections contribute to increased mortality and morbidity rates among geriatric individuals, nursing home residents and those with organ dysfunction. Patients with end-stage liver or renal disease, as well as those hospitalized in intensive care units (ICUs), face a significant risk of acquiring hospital-associated MRSA. Fatality rates, ranging from 5 to 60%, vary depending on the patient group and infection site, as revealed by the study. Additionally, research findings indicate that more than 60% of patients contract MRSA within 48 hours of hospitalization, regardless of pre-existing healthcare risks. Consequently, these factors are anticipated to drive the demand for MRSA drugs, which are propelling the growth of Methicillin-resistant Staphylococcus Aureus Drugs Market during the estimated period. Moreover, the surge research activities to develop novel MRSA drugs by key players, as well as increasing number of favorable government initiatives present various lucrative opportunities over the forecast years. However, the lack of systematic surveillance for MRSA infection in developing countries and the high cost of novel MRSA drugs are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Methicillin-resistant Staphylococcus Aureus Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with the largest market share owing to the increasing prevalence of MRSA infections, enhanced healthcare infrastructure, and the robust presence of domestic firms actively involved in researching and developing MRSA drugs aimed at combating infections originating in healthcare settings due to MRSA. Companies offering their products in the North American market include Pfizer Inc., GSK plc., Proctor & Gamble, Novartis AG, among others. Additionally, government support and initiatives from public health agencies to combat MRSA infections are expected to further fuel market expansion. For instance, in October 2020, the United States Centers for Disease Control and Prevention (CDC) announced the ""National Action Plan"" to address antibiotic-resistant infections, aiming to expedite efforts to prevent their spread within five years. Consequently, the development and launch of novel drugs in the United States and Canada are expected to bolster the regional market. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The growing burden of MRSA infection among the population, emergence of MDR-MRSA strains, resistant to multiple antibiotics, rising focus on developing new treatment options, along with increased healthcare expenditure are significantly propelling the market demand across the region.

Major market players included in this report are:
Cumberland Pharmaceuticals Inc
Pfizer Inc
AbbVie Inc.
Melinta Therapeutics Inc
Merck & Co Inc
Theravance Biopharma
Basilea Pharmaceutica
AmpliPhi Biosciences Corporation
Teva Pharmaceutical Industries ltd
Debiopharm International S.A.

Recent Developments in the Market:
 In 2023, Basilea Pharmaceutica Ltd announced the submission of a new drug application (NDA) to the U.S. FDA. The application pertains to the treatment of patients across three indications: Staphylococcus aureus bacteremia (SAB), including acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and right-sided infective endocarditis.
 In July 2021, Melinta Therapeutics introduced KIMYRSA (oritavancin), an antibiotic of the lipoglycopeptide class. KIMYRSA provides a comprehensive treatment regimen for acute bacterial skin and skin structure infections (ABSSSI) triggered by susceptible strains of designated Gram-positive microorganisms, encompassing methicillin-resistant Staphylococcus aureus (MRSA).
 In January 2020, Wockhardt unveiled regulatory approval for two groundbreaking antibiotics, EMROK (IV) and EMROK O (Oral), in India. These medications are designed to combat acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteremia. They specifically target superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA), addressing the pressing issue of escalating antimicrobial resistance.

Global Methicillin-resistant Staphylococcus Aureus Drugs Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Drug Class, Route of Administration, Distribution Channel, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:
Lipopeptides
Oxazolidinones
Cephalosporin
Tetracycline
Folate Antagonist
Other Drug Classes

By Route of Administration:
Oral Administration
Parenteral Administration

By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Cumberland Pharmaceuticals Inc
Pfizer Inc
AbbVie Inc.
Melinta Therapeutics Inc
Merck & Co Inc
Theravance Biopharma
Basilea Pharmaceutica
AmpliPhi Biosciences Corporation
Teva Pharmaceutical Industries ltd
Debiopharm International S.A.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.